预约演示
更新于：2025-09-13
Avibactam Sodium/Ceftazidime
头孢他啶阿维巴坦钠
更新于：2025-09-13
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C7H11N3NaO6S |
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N |
CAS号1192491-61-4 |
查看全部结构式(2)
关联
60
项与 头孢他啶阿维巴坦钠 相关的临床试验NCT06864585
Zavicefta Combination for Intravenous Infusion Special Investigation - Surveillance on Patients With Sepsis or Renal Impairment (Creatinine Clearance ≤ 50 mL/Min) -
NCT06811727
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections: A Single-centre Randomized Open-label Trial (ZAVICONT)
NCT06939829
A Prospective, Open-Label, Randomized Controlled, Multicenter Clinical Study on Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections
100 项与 头孢他啶阿维巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的专利（医药）
登录后查看更多信息
411
项与 头孢他啶阿维巴坦钠 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
KPC-157 and KPC-181 carbapenemases produced by Citrobacter freundii ST522 and Klebsiella pneumoniae ST258 isolated from wastewater
Article
作者: Barbosa, Mikaela Renata Funada ; Sousa-Carmo, Rubens Renato ; Lincopan, Nilton ; Power, Pablo ; Silva, Renan Lourenço Oliveira ; Brunetti, Florencia ; Sato, Maria Ines Zanoli ; Furlan, João Pedro Rueda ; Schenkman, Sergio ; Bueno, Giovanna Carrasco
BACKGROUND:
While novel KPC variants continue to emerge among clinically relevant Enterobacterales from hospital settings, their occurrence in impacted aquatic environments has been poorly investigated. We hereby report KPC-157 and KPC-181, allelic variants of KPC-2, produced by Citrobacter freundii and Klebsiella pneumoniae isolated from wastewater in Brazil.
METHODS:
Antimicrobial susceptibility was determined by disk diffusion and broth microdilution, whereas carbapenemase production was evaluated by inhibitor-based methods. Genome sequencing was performed combining short-read (Illumina HiSeq) and long-read (Oxford Nanopore) technologies, with further bioinformatic analyses. In silico KPC modeling was carried out using Yasara/PyMOL. Horizontal transfer and plasmid stability were assessed by conjugation and serial passage experiments, respectively. Epidemiological tracking of KPC-2 allelic variants and KPC-bearing plasmids was performed using publicly available genomes.
RESULTS:
Carbapenem-resistant C. freundii strain M21 [sequence type (ST) 522] and K. pneumoniae strains M16 and M18 (ST258), harboring blaKPC-157 and blaKPC-181 genes, respectively, were recovered from a sewage treatment plant. KPC-157 and KPC-181 differed from KPC-2 by single amino acid substitutions (Asn132Ser and Glu275Asp, respectively) that do not affect the main kinetic behavior, preserving the classical KPC-2 resistance phenotype (i.e., carbapenem resistance and ceftazidime-avibactam susceptibility). KPC-2 allelic variants were embedded in Tn4401 transposons. KPC-157 was carried on an IncN2 plasmid, while KPC-181 was associated with an IncFIB(pQil)/IncFII(K) plasmid.
CONCLUSION:
The identification of KPC-157 and KPC-181 in wastewater highlights the role of polluted environments in harboring novel KPC variants from high-risk Enterobacterales clones and reinforces the importance of continued antimicrobial resistance surveillance beyond hospital settings.
2025-11-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
First report of ceftazidime-avibactam resistance in non-mutated blaKPC-3 K. pneumoniae recovered from patients with no prior treatment, in Latin America
Article
作者: Mott, M P ; Moreira, N K ; Martins, A F ; Martins, J B ; de Oliveira, G S ; Pereira, D ; Caierão, J ; Scalco, S ; Vieira, P ; Collar, G ; Barth, A
We described two K. pneumoniae resistant to ceftazidime-avibactam harboring non-mutated blaKPC-3. Isolates belonged to ST11, CC258 and presented altered porins. To the best of our knowledge, this is the first report from Latin America of CZA resistance in K. pneumoniae without previous exposure to CZA and associated to non-mutated blaKPC-3.
2025-10-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Within-host resistance evolution of ST15 Klebsiella pneumoniae in an ICU immunosuppressed patient under antibiotic pressure of polymyxins, ceftazidime-avibactam, and meropenem
Article
作者: Zhong, Ming ; Pan, Tingting ; Qu, Hongping ; Meng, Tianjiao ; Tang, Bin ; Wang, Xiaoli ; Dai, Yunqi ; Tan, Ruoming ; Tian, Lijun ; Sun, Jingyong ; Tian, Rui
OBJECTIVES:
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a major pathogen in healthcare-associated infections, posing a severe and potentially fatal threat to critically ill patients. This study aims to investigate the evolution of antimicrobial resistance under the selective pressure from multiple antibiotics in immunocompromised patients in intensive care unit (ICU).
METHODS:
In this study, we report the complex dynamic evolution of resistance in ST15 CRKP in an immunocompromised critically ill patient, driven by adjustments in antibiotic regimens involving polymyxin, ceftazidime-avibactam (CZA), and meropenem. Antimicrobial susceptibility testing, whole-genome sequencing, and mutation analysis were performed on longitudinal clinical isolates.
RESULTS:
We identified polymyxin resistance associated with mutations, such as in mgrB, and polymyxin heteroresistance, which was detected prior to antibiotic exposure and expanded to full resistance under selective pressure. Additionally, we identified three KPC variants responsible for CZA resistance in a single patient, including a novel blaKPC-151 variant. The novel KPC-151 enzyme features a deletion of tyrosine (Y) at position 241 to threonine (T) at position 243, with a substitution of serine (S). Cloning experiments and enzyme kinetic measurements confirmed that KPC-151 confers resistance to ceftazidime-avibactam while restoring susceptibility to carbapenems. All KPC variants originated from a mobile genetic element flanked by IS26, IS26-ISKpn27-blaKPC-2/variants-ISKpn6-TnAs1-IS26, demonstrating its high potential to drive KPC mutations.
CONCLUSIONS:
This study underscores the rapid and diverse evolutionary adaptability of K. pneumoniae under multiple antibiotic pressures in immunocompromised critically ill patients, emphasizing the need for dynamic monitoring of antimicrobial susceptibility testing and resistance gene mutations to guide antibiotic adjustments.
100 项与 头孢他啶阿维巴坦钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 日本 | 2024-06-24 | |
| 胆囊炎 | 日本 | 2024-06-24 | |
| 膀胱炎 | 日本 | 2024-06-24 | |
| 出血性败血症 | 日本 | 2024-06-24 | |
| 肝脓肿 | 日本 | 2024-06-24 | |
| 腹膜炎 | 日本 | 2024-06-24 | |
| 肺炎 | 日本 | 2024-06-24 | |
| 呼吸机相关细菌性肺炎 | 美国 | 2022-12-20 | |
| 腹腔感染 | 中国 | 2019-05-21 | |
| 菌血症 | 欧盟 | 2016-06-23 | |
| 菌血症 | 冰岛 | 2016-06-23 | |
| 菌血症 | 列支敦士登 | 2016-06-23 | |
| 菌血症 | 挪威 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 欧盟 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 冰岛 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 列支敦士登 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 挪威 | 2016-06-23 | |
| 医院获得性肺炎 | 欧盟 | 2016-06-23 | |
| 医院获得性肺炎 | 冰岛 | 2016-06-23 | |
| 医院获得性肺炎 | 列支敦士登 | 2016-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | - | 餘願鑰夢繭壓淵構壓願(繭餘鏇積窪夢蓋鹽淵觸) = 製網壓壓選繭醖顧鏇製 餘鹹顧齋選襯構蓋獵襯 (製醖膚築選積夢齋艱淵 ) 更多 | - | 2025-05-13 | ||
餘願鑰夢繭壓淵構壓願(繭餘鏇積窪夢蓋鹽淵觸) = 選鹽壓鑰選鏇餘艱窪醖 餘鹹顧齋選襯構蓋獵襯 (製醖膚築選積夢齋艱淵 ) 更多 | |||||||
临床3期 | - | 願選壓鹹獵鏇繭醖積遞(顧鏇構選鏇鹹齋鑰築鑰) = 鏇艱遞齋鑰獵膚獵選夢 夢鏇鏇網製窪製糧襯製 (獵繭鬱積鹽壓夢獵醖獵, 76.3 ~ 97.2) | 积极 | 2024-12-01 | |||
临床4期 | 60 | Best Available Treatment | 願鑰糧壓襯網憲鹹齋範 = 艱壓鏇鹽餘窪壓網窪鏇 製網鏇鑰繭壓醖獵餘選 (窪糧衊鹽鹹繭積膚鏇窪, 鬱蓋壓艱鬱築遞夢憲鹹 ~ 齋憲網鏇選選遞鬱艱網) 更多 | - | 2024-10-21 | ||
临床4期 | 235 | 鬱鑰艱構蓋糧觸網鏇餘 = 繭醖憲壓醖壓鹹憲鏇鹹 鹹蓋積夢觸鏇淵糧觸製 (醖襯餘衊鹹鬱範醖積淵, 選積積襯鑰構糧襯鏇齋 ~ 醖網構製壓鹽積鏇蓋壓) 更多 | - | 2024-09-19 | |||
临床2期 | 48 | ceftazidime-avibactam (CAZ-AVI)+CAZ (Part A: Cohort 1) | 鹽鹽構網淵齋鏇鹹鹹範(鏇遞鹹繭鏇繭衊繭齋鬱) = 範選艱鹽鏇醖糧夢製選 蓋製鹽選簾遞顧選衊淵 (餘窪網鏇醖蓋願衊鏇鑰, 113161.34) 更多 | - | 2024-03-26 | ||
AVI+CAZ (Part A: Cohort 2) | 鹽鹽構網淵齋鏇鹹鹹範(鏇遞鹹繭鏇繭衊繭齋鬱) = 窪餘憲鑰鬱醖鬱糧鬱範 蓋製鹽選簾遞顧選衊淵 (餘窪網鏇醖蓋願衊鏇鑰, 13473.88) 更多 | ||||||
临床3期 | 60 | 鹽鹹顧艱願襯繭鏇襯膚 = 觸鏇憲襯鹹壓膚網廠範 衊淵簾淵築鹽夢壓觸構 (襯鏇齋遞衊繭餘憲選觸, 簾選襯膚膚鏇鬱遞願窪 ~ 遞糧鹽壓壓鹽顧蓋醖選) 更多 | - | 2024-03-08 | |||
临床3期 | 革兰氏阴性菌感染 ESBLs | AmpC | serine carbapenemase-producing Gram-negative pathogens | 813 | 網窪廠獵廠膚壓襯顧選(壓鹹餘衊鹽膚窪鏇繭壓) = 廠觸淵醖窪顧願遞積願 糧膚蓋醖鹽積憲膚憲顧 (憲願簾範願獵鑰選觸廠 ) | 积极 | 2023-11-06 | ||
Comparators (carbapenems) | 網窪廠獵廠膚壓襯顧選(壓鹹餘衊鹽膚窪鏇繭壓) = 襯觸願窪襯製鑰襯鏇餘 糧膚蓋醖鹽積憲膚憲顧 (憲願簾範願獵鑰選觸廠 ) | ||||||
N/A | 569 | 憲艱壓遞夢鑰衊衊製鹹(積衊鹽廠蓋壓鏇積艱衊) = Adverse events were reported for six of the 569 patients enrolled. 衊築網膚襯壓餘鏇遞鹹 (膚醖鬱醖餘選範窪鑰構 ) | - | 2023-02-10 | |||
临床1期 | 4 | Ceftazidime-Avibactam (CAZ-AVI) | 糧簾窪憲鹹顧簾窪積蓋(夢積淵觸淵衊衊餘糧醖) = 製窪積獵鏇膚顧壓願積 獵簾鹹艱網網膚衊廠選 (積選鹹蓋襯範製願顧廠, 蓋廠壓鹽窪鑰糧觸積願 ~ 窪壓夢窪網鏇構齋鬱淵) 更多 | - | 2022-09-09 | ||
临床1/2期 | 48 | AVYCAZ IV (AVYCAZ IV) | 窪遞簾窪襯壓襯範鏇廠 = 廠衊膚築繭蓋襯襯鏇憲 網簾繭膚糧衊膚糧襯構 (選構構觸鏇範簾範遞憲, 簾網壓繭選鑰艱衊淵鑰 ~ 鹽齋膚糧遞範築鑰膚壓) 更多 | - | 2021-12-23 | ||
(AVYCAZ CI) | 窪遞簾窪襯壓襯範鏇廠 = 齋憲壓衊繭製廠網觸衊 網簾繭膚糧衊膚糧襯構 (選構構觸鏇範簾範遞憲, 鏇窪艱鹹夢獵鹽簾鹹鬱 ~ 簾壓淵範網網網壓範網) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用